Revenues for the first quarter of 2013 were consistent with revenues recorded in the first quarter of 2012.

In the first quarter of 2013, R&D expense increased by $3.3 million compared to 2012 and was primarily a result of increased clinical trial costs of $2.3 million and contract manufacturing costs of $0.5 million primarily due to our late-stage rindopepimut program.

G&A expense in the first quarter of 2013 increased by $0.8 million from $2.3 million in 2012 due primarily to higher personnel-related expenses and rindopepimut-related commercial planning costs in 2013.

During the quarter ended March 31, 2013, the increase in cash, cash equivalents and marketable securities of $98.4 million from December 31, 2012 primarily reflects the issuance of 16.2 million shares of common stock during the quarter through our Cantor ATM facility and an underwritten public offering that raised aggregate net proceeds to Celldex of $114.1 million, partially offset by our first quarter operations-related cash burn of approximately $16.1 million.

As of March 31, 2013, Celldex had approximately 80.9 million shares outstanding.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization (by Celldex and others) of rindopepimut ( CDX-110), CDX-011, CDX-1135, CDX-1401, CDX-1127, CDX-301, Belinostat and other products . Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of rindopepimut, CDX-011 and other drug candidates, our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; our ability to adapt our APC Targeting Technology TM to develop new, safe and effective vaccines against oncology and infectious disease indications; our ability to successfully complete product research and further development of our programs; the uncertainties inherent in clinical testing; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage research and development efforts for multiple products at varying stages of development; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
 (In thousands, except per share amounts) 
 OF OPERATIONS DATA  Ended March 31,
  2013 2012
 Product Development and Licensing Agreements   $ 30  $ 35
 Contracts and Grants   50  54
 Product Royalties   2,334  2,344
 Total Revenue   2,414  2,433
 Research and Development   14,090  10,769
 Royalty   2,334  2,344
 General and Administrative   3,138  2,317
 Amortization of Acquired Intangible Assets   253  291
 Total Operating Expense   19,815  15,721
 Operating Loss   (17,401)  (13,288)
 Investment and Other Income, Net   379  205
 Interest Expense   (310)  (433)
 Net Loss   $ (17,332)  $ (13,516)
 Basic and Diluted Net Loss per     
 Common Share   $ (0.23)  $ (0.27)
 Weighted Average Common     
 Shares Outstanding   74,027  50,145
 BALANCE SHEETS DATA  March 31, December 31,
  2013 2012
 Cash, Cash Equivalents and Marketable Securities   $ 182,377  $ 83,962
 Other Current Assets   2,076  1,152
 Property and Equipment, net   7,131  7,205
 Intangible and Other Assets, net   32,781  33,222
 Total Assets   $ 224,365  $ 125,541
 Current Liabilities   $ 18,330  $ 17,685
 Long-Term Liabilities   11,094  12,082
 Stockholders' Equity   194,941  95,774
 Total Liabilities and Stockholders' Equity   $ 224,365  $ 125,541
CONTACT: Sarah Cavanaugh         Vice President of Investor Relations &         Corp Communications         Celldex Therapeutics, Inc.         (781) 433-3161

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today